Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How PTSA Tracers Simplify Cooling Water Treatment

A More Accurate and Safer Process Scale and corrosion in cooling tower systems can reduce heat transfer efficiency and cause unexpected equipment failures. While scale and corrosion inhibitors added to the water supply can minimize these occurrences, maintaining treatment levels within the control limits necessary to optimize performance and minimize costs can be a challenge. Let’s…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

A More Accurate and Safer Process

Scale and corrosion in cooling tower systems can reduce heat transfer efficiency and cause unexpected equipment failures. While scale and corrosion inhibitors added to the water supply can minimize these occurrences, maintaining treatment levels within the control limits necessary to optimize performance and minimize costs can be a challenge. Let’s take a look at a more accurate and safer process for controlling inhibitor levels over traditional methods.

The Traditional Method of Adding Inhibitor Products

Typically, inhibitor products are added to the tower water in direct proportion to the fresh water makeup. However, consistent inhibitor levels may not be maintained if the conductivity of the water makeup varies, there are multiple water supply sources, and/or treatment pumps lose prime. Using traditional feed methods under these conditions may lead to poor system control. Sometimes too little inhibitor is added, leading to cooling tower corrosion and scale formation that can impact system performance. Other times, too much inhibitor may be added, a wasteful practice that can leave deposits behind.

Fluorescent-Traced Product Feed and Control Systems

Fluorescent-traced product feed and control systems can help address these concerns. In this method, a colorless fluorescent dye called PTSA is added to the cooling water inhibitor, serving as a treatment level tracer. PTSA levels can be accurately measured in about 30 seconds using a handheld or in-line fluorometer, requiring no harmful chemical reagents. Unlike other tracers, such as molybdenum, PTSA is more environmentally friendly and is not typically subject to discharge restrictions.

Chem-Aqua’s aquaDART® Technology

Knowing when and where PTSA products should be applied ensures the success of an inhibitor treatment. That’s why Chem-Aqua performed extensive research into the limiting factors that must be considered when using PTSA. Our R&D, Product Management, and Equipment groups used the information they gathered to design our aquaDART® online monitoring, control, and chemical feed system for cooling towers.

Chem-Aqua’s aquaDART® technology allows for quick, accurate measurement of PTSA-based products. The system uses real-time sensors to directly measure key parameters to control scale and corrosion levels. When paired with a web-enabled controller, PTSA levels can be continuously monitored and adjusted to maintain them within 1% to 2% of the target concentration. The system can be board mounted for quick and accurate installation, and treatment levels can be easily verified using a hand-held meter.

aquaDART® Provides Precision Control

Safe, effective water treatment to control corrosion and scale in cooling tower systems is essential. The cutting-edge Chem-Aqua aquaDART® PTSA-traced product feed and control system is state-of-the-art automation for monitoring and controlling water treatment programs. aquaDART® helps facilities precisely control inhibitor levels and provides real-time alerts when levels are out of range, improving cooling tower performance while reducing water, energy, and labor costs.

To learn more, visit https://www.chemaqua.com/en-us/Services/Innovations/aquaDART-Automation-Control-Systems today.

Read more at chemaqua.com

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512